News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,995 Results
Type
Article (14915)
Company Profile (299)
Press Release (266775)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79886)
Career Advice (163)
Deals (13341)
Drug Delivery (39)
Drug Development (50706)
Employer Resources (31)
FDA (5852)
Job Trends (5174)
News (145157)
Policy (10074)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (922)
Accelerated approval (19)
Adcomms (14)
Allergies (85)
Alliances (21789)
ALS (126)
Alzheimer's disease (1035)
Antibody-drug conjugate (ADC) (243)
Approvals (6047)
Artificial intelligence (265)
Autoimmune disease (118)
Automation (9)
Bankruptcy (105)
Best Places to Work (4565)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (46)
Breast cancer (347)
Cancer (3158)
Cardiovascular disease (239)
Career advice (148)
Career pathing (8)
CAR-T (222)
CDC (5)
Cell therapy (573)
Cervical cancer (14)
Clinical research (43720)
Collaboration (1163)
Company closure (2)
Compensation (602)
Complete response letters (41)
COVID-19 (1101)
CRISPR (86)
C-suite (564)
Cystic fibrosis (112)
Data (4354)
Denatured (15)
Depression (93)
Diabetes (256)
Diagnostics (1385)
Digital health (12)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (195)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (218)
Earnings (31674)
Editorial (26)
Employer branding (4)
Employer resources (29)
Events (51722)
Executive appointments (629)
FDA (7617)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (10)
Frontotemporal dementia (22)
Funding (992)
Gene editing (183)
Generative AI (22)
Gene therapy (495)
GLP-1 (507)
Government (1149)
Grass and pollen (3)
Guidances (166)
Healthcare (6621)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (194)
Immuno-oncology (43)
Indications (70)
Infectious disease (1210)
Inflammatory bowel disease (157)
Inflation Reduction Act (10)
Influenza (40)
Intellectual property (169)
Interviews (18)
IPO (7348)
IRA (13)
Job creations (867)
Job search strategy (130)
JPM (40)
Kidney cancer (9)
Labor market (23)
Layoffs (243)
Leadership (10)
Legal (1401)
Liver cancer (41)
Longevity (11)
Lung cancer (424)
Lymphoma (251)
Machine learning (24)
Management (7)
Manufacturing (379)
MASH (131)
Medical device (2669)
Medtech (2678)
Mergers & acquisitions (6625)
Metabolic disorders (732)
Multiple sclerosis (104)
NASH (13)
Neurodegenerative disease (233)
Neuropsychiatric disorders (70)
Neuroscience (1963)
Neurotech (1)
NextGen: Class of 2026 (2037)
Non-profit (866)
Now hiring (31)
Obesity (333)
Opinion (125)
Ovarian cancer (132)
Pain (102)
Pancreatic cancer (164)
Parkinson's disease (232)
Partnered (12)
Patents (305)
Patient recruitment (343)
Peanut (44)
People (26692)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15492)
Phase 2 (20315)
Phase 3 (12828)
Pipeline (3340)
Policy (91)
Postmarket research (853)
Preclinical (6540)
Press Release (30)
Prostate cancer (147)
Psychedelics (50)
Radiopharmaceuticals (239)
Rare diseases (660)
Real estate (1450)
Recruiting (12)
Regulatory (9919)
Reports (19)
Research institute (973)
Resumes & cover letters (19)
Rett syndrome (24)
RNA editing (21)
RSV (17)
Schizophrenia (124)
Series A (185)
Series B (140)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2006)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (339)
Venture capital (69)
Weight loss (174)
Women's health (26)
Worklife (2)
Date
Today (70)
Last 7 days (297)
Last 30 days (1150)
Last 365 days (17871)
2026 (1913)
2025 (18104)
2024 (20548)
2023 (22419)
2022 (26829)
2021 (27810)
2020 (23363)
2019 (16249)
2018 (11763)
2017 (13767)
2016 (11848)
2015 (14360)
2014 (10399)
2013 (7487)
2012 (7539)
2011 (7620)
2010 (7429)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18273)
Australia (3114)
California (7130)
Canada (1852)
China (781)
Colorado (249)
Connecticut (255)
Delaware (236)
Europe (39209)
Florida (911)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (396)
India (36)
Indiana (162)
Iowa (8)
Japan (227)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (738)
Massachusetts (5625)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (33)
New Hampshire (21)
New Jersey (1657)
New Mexico (13)
New York (1774)
North Carolina (836)
North Dakota (6)
Northern California (3510)
Ohio (179)
Oklahoma (11)
Oregon (24)
Pennsylvania (1287)
Puerto Rico (9)
Rhode Island (25)
South America (215)
South Carolina (9)
Southern California (2826)
Tennessee (40)
Texas (918)
United States (23505)
Utah (97)
Virginia (137)
Washington D.C. (37)
Washington State (593)
West Virginia (1)
Wisconsin (46)
281,995 Results for "scribe therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Scribe Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 16, 2025
·
1 min read
Press Releases
Scribe Therapeutics Projected to Enter the Clinic in Mid-2026 with STX-1150, a PCSK9-targeting CRISPR Epigenetic Silencing Therapy for Durable LDL-C Reduction
January 20, 2026
·
8 min read
Press Releases
Scribe Therapeutics to Demonstrate Scientific and Corporate Leadership at Upcoming Conferences
August 26, 2025
·
2 min read
Press Releases
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
November 18, 2025
·
7 min read
Press Releases
Scribe Therapeutics Highlights Latest Data on Lp(a)-Lowering Therapy and Novel AI Platform for Next-Generation CRISPR-Based Therapeutics at Two Premier Conferences
September 10, 2025
·
5 min read
Press Releases
Scribe Therapeutics to Participate in Upcoming March 2025 Conferences
February 27, 2025
·
2 min read
Press Releases
Scribe Therapeutics Reports Positive Preclinical Data on its Novel CRISPR Technologies at the 2025 EAS Congress and ASGCT Annual Meeting
May 22, 2025
·
5 min read
Press Releases
Scribe Therapeutics Achieves Milestone for In Vivo Program in Collaboration with Sanofi
January 13, 2025
·
2 min read
Press Releases
Scribe Therapeutics to Unveil Latest Preclinical Data on Proprietary CRISPR Epigenetic Silencing Technology for LDL-C Lowering at the 2025 EAS Congress
April 23, 2025
·
2 min read
Biotech Bay
Scribe Therapeutics Expands In Vivo Collaboration with Sanofi to Second Target
Scribe Therapeutics Inc. announced that Sanofi has exercised its option for a second target as part of the companies’ research collaboration to develop in vivo CRISPR-based therapeutics.
January 3, 2024
·
2 min read
1 of 28,200
Next
